Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2013-03-14 Regulatory Filings
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Release of Shares from Escrow 1 page 315.0KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Bioxyne Limited to the Australian Securities Exchange regarding the release of shares from escrow. It references Listing Rule 3.10A and details the number of shares being released and remaining in escrow, along with historical context about the escrow initiation and takeover completion. There is no financial data, no detailed report, or presentation content. The document is an official regulatory announcement about share escrow status, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change (SHA) because it does not announce new share issuance but rather the release of shares from escrow. The document length is short and it is an announcement rather than a report or detailed filing.
2013-03-14 English
Appendix 3B and s708A(6) Notice - Completion of Placement 13 pages 986.5KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement related to a new issue of shares by Bioxyne Limited, including a Section 708A(6) Notice under the Corporations Act 2001 (Cth) and an Appendix 3B form. Appendix 3B is a standard form used by companies listed on the Australian Securities Exchange (ASX) to announce new issues of securities and apply for quotation of additional securities. The content includes specifics about the number of shares issued, issue price, purpose of the issue, underwriting details, and compliance with ASX rules. This type of document is a capital/financing update as it informs the market and shareholders about new share issuance and related capital raising activities. It is not a full financial report, earnings release, or regulatory filing unrelated to capital changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2013-03-06 English
Vitality Devices Acquisition Update 1 page 96.1KB
M&A Activity Classification · 95% confidence The document is a short announcement from Bioxyne Limited regarding an update on a proposed acquisition of VITALITY Devices Pty Limited. It mentions ASX confirmations related to listing rules and shareholder approval conditions. The text does not contain detailed financial statements or comprehensive report data but rather provides an update on a corporate transaction. The document length is only 1561 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements related to merger proposals or takeover bids.
2013-03-03 English
Half Yearly Report and Accounts to 31 December 2012 21 pages 2.2MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D – Half Year Report' and includes detailed financial statements such as the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Statement of Financial Position, and notes to the financial statements for the half-year ended 31 December 2012. It also contains a Directors' Report, Auditor's Independence Declaration, and other comprehensive financial data. The presence of actual financial statements and detailed analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2013
2013-02-27 English
Suspension from Official Quotation 1 page 29.8KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing the suspension of Bioxyne Limited's securities from official quotation. It references a listing rule and mentions a pending announcement related to a share placement and acquisition proposal. The content is an official notice about trading suspension, not a financial report, audit, or management information. It fits the category of a regulatory announcement related to listing compliance rather than a detailed report or financial update. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is short and is an announcement, not a report itself.
2013-02-19 English
Suspension Request 1 page 71.5KB
Delisting Announcement Classification · 90% confidence The document is a formal letter addressed to the Australian Securities Exchange (ASX) requesting a suspension of the company's securities from trading. It references ASX Listing Rule 17.2 and states the suspension is due to the company completing an underwritten placement, with a forthcoming announcement about the placement's completion. The document is short (1080 characters) and is clearly an announcement related to trading status rather than a financial report or detailed filing. This fits the definition of a Delisting Announcement (DLST) or a trading suspension notice. Since the document specifically requests suspension of trading (not delisting), it aligns best with the Delisting Announcement category as the closest match for suspension notices in this classification scheme.
2013-02-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.